Abstract:Background: Sickle cell disease is one of the most common genetic diseases in France. In French Guiana, neonatal screening was introduced in 1992, at the same time as other screening programs for childhood diseases. The aim of this study is to describe the organization of newborn screening for sickle cell disease in French Guiana. Materials and methods: We used several data sources: data collected from hospital records since 2005, activity reports from the national neonatal screening program and data from screening campaigns organized by the Drepaguyane association between 2010 and 2021 on 1,300 subjects. Blood samples from newborns are collected by capillary or venous sampling and absorbed on blotting paper (Guthrie) at the same time as those for other neonatal screenings. The dried papers are sent to the inter-regional laboratory in Lille, for further processing. In Saint-Laurent-du-Maroni, in order to reduce the proportion of people lost to follow-up, a double screening is carried out and the results are returned before discharge from the maternity hospital. All data were entered into an anonymous Excel file. The data were analyzed using STATA software. Results: Among the 175,593 screened neonates between 1992 and 2021, screening detected 823 infants with sickle cell disease and 17,950 heterozygotes. Sickle cell genotypes include 493 SS (60%), 302 SC (37%) and 28 S-Beta-thalassemia (3%). The incidence of sickle cell disease was 1/213, 95% CI [1/236-1/204], and that of heterozygotes 1/10, IC 95% [1/12-1/8]. The majority of these children (52%) were from the Maroni region. The delay between screening and test results was 7 days. Only pathological results (homozygous, heterozygous) were communicated to parents and/or the attending physician by post. These data confirm the upward trend in the number of children screened for sickle cell disease in French Guiana. Data from screening campaigns organized by the Drepaguyane association have enabled to describe the distribution of the various abnormal hemoglobin fractions, and to confirm that HbS is more frequent in Western French Guiana. In Cayenne, in 2021, the active file comprised 699 patients, including 266 children under 18 years old. Discussion and conclusion: This study provides valuable data on 30 years of neonatal screening for sickle cell disease in French Guiana, and on the evolution of sickle cell disease patients. It confirms that French Guiana is the French territory with the highest incidence of sickle cell disease. This incidence continues to rise over time. The study reveals the improvement in the organization of sickle cell disease management in French Guiana between 1992, when screening was introduced, and the present day. It highlights the role of patient associations in the fight against this disease, by organizing awareness and screening campaigns. These data will be used to guide public health policies in the pursuit of improved care and primary prevention.

Cross-sectional prospective feasibility study of newborn screening for sickle cell anaemia and congenital hypothyroidism in Guyana

A Multicenter Prospective Study of Next-Generation Sequencing-Based Newborn Screening for Monogenic Genetic Diseases in China

Newborn Screening in Zhejiang, China

[Retrospective Study on Neonatal Screening for Congenital Hypothyroidism and Phenylketonuria in China in the Past 22 Years].

Neonatal screening for congenital hypothyroidism and phenylketonuria in China

Newborn Screening for Sickle Cell Disease Using Point-of-Care Testing in Low-Income Setting

Newborn Screening for Selected Disorders in Nepal: A Pilot Study

Newborn Screening for Congenital Hypothyroidism and Congenital Adrenal Hyperplasia

Experiences and Challenges with Congenital Hypothyroidism Newborn Screening in Indonesia: A National Cross-Sectional Survey

Introduction of a national program for HbA1c testing in Guyana South America and initial results

[Sickle cell disease in French Guiana: assessing 30 years of neonatal screening (1992-2021)]

The Alberta Newborn Screening Approach for Sickle Cell Disease: The Advantages of Molecular Testing

Fifty years of newborn screening for congenital hypothyroidism: current status in Australasia and the case for harmonisation

An insight into Indonesia's progress for newborn screening program: What is currently going on

International Newborn Screening: Where Are We in Saudi Arabia?

First Experiences with Newborn Screening for Congenital Hypothyroidism in Ulaanbaatar, Mongolia

Sustainability of newborn screening for sickle cell disease in resource-poor countries: A systematic review

Newborn Screening for Inherited Metabolic Diseases Using Tandem Mass Spectrometry in China: Outcome and Cost-Utility Analysis

Outcome of Expanded Newborn Screening Among 194 000 Neonates at Northeast México

Perspective on newborn screening (NBS): Evidence sharing on conditions to be included in NBS in Pakistan

Barriers and facilitators to community acceptability of integrating point-of-care testing to screen for sickle cell disease in children in primary healthcare settings in rural Upper East Region of Northern Ghana